sector medic suppli devic
 fire almost cylind rais pt
reiter buy
messag abbott result showcas breadth top line momentum
four busi segment top organ growth compani overal deliv
best revenu growth quarter sinc expect see anoth
quarter anytim soon view perform valid thesi
abbott right mix busi product cycl sustain growth
forese futur outlook believ warrant premium valuat vs peer
rais pt reiter buy rate
fire almost cylind abbott deliv impress perform
revenu rise organ basi ep cc upsid
rel consensu concentr mostli nutrit diabet segment
diagnost establish pharma also top street expect handili
account currenc shift meaning quarter accur
reflect estim four busi unit grew better manag
rais full year guidanc suggest much
momentum expect continu balanc year
strong perform came despit mix result medic devic
segment rhythm manag neuromodul disappoint
know boston report point estim abbott like
grew line market cede ground pacemak issu
low power stem combin tough comp lack crt-p mri label
 latter manag hope resolv meanwhil
line growth high power side still like view disappoint given
mri approv abbott secur replac headwind
obscur solid gain de novo implant elsewher neuromodul growth deceler
franchis worst perform three year
manag chalk shortfal sloppili execut sale forc expans
suspect competit dynam may also play role current
enjoy renew momentum follow protract period under-perform also
monitor see market growth final start ebb year gain
essenti mid-singl digit growth market
headwind off-set upsid diabet electrophysiolog
structur heart libr revenu rose yoy sale
doubl sequenti abbott exit patient treat global
remain track top estim compani instal base
exce full year model libr revenu
includ domest sale meanwhil abbott ep result show afib ablat
remain one underappreci growth market med-tech view
estim world-wide market grew constant currenc basi driven
strong result abbott track top abbott
ep segment also benefit roll-out confirm implant cardiac monitor
estim captur icm market two quarter
launch structur heart mitraclip grew track
product year coapt result septemb repres potenti catalyst
improv momentum domest
price target reiter buy model call adjust ep
total revenu organ compar
prior forecast respect long-term continu see
abbott sustain top bottom line grower outlook believ
warrant premium valuat vs large-cap med-tech peer price target
base multipl forward ntm ep estim signific
upsid potenti target current level reiter buy rate
page analyst certif import disclosur
abbott one largest healthcar compani world boast top line
lead franchis across medic devic diagnost nutrit establish
pharmaceut segment path get point long wind one
abbott reshuffl portfolio sever time past two decad recent
acquisit st jude medic aler dust settl
deal abbott emerg premium grower within large-cap med-tech group
model call compani deliv top bottom line gain
respect compar averag peer yet
stock trade today modest premium group ntm ep vs
provid opportun rel multipl expans visibl sustain
growth trajectori improv
abbott share current trade ntm ep estim ntm
ebitda modestli large-cap med-tech averag
respect believ abbott above-averag growth profil peg
top bottom line respect vs group averag
warrant premium valuat rais price target previous
base unchang multipl forward ntm ep estim
signific upsid potenti target current level assign abbott buy rate
downsid risk rate price target includ integr challeng relat
st jude aler acquisit pipelin setback and/or neg clinic result
impact abbott competit adopt key new product libr alin
etc fall short street expect
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
point
compani report guggenheim secur llc estim
page analyst certif import disclosur
